- Home
- PAYC vs JAZZ Comparison
PAYC vs JAZZ Comparison
Compare PAYC & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYC
- JAZZ
- Stock Information
- Founded
- PAYC 1998
- JAZZ 2003
- Country
- PAYC United States
- JAZZ Ireland
- Employees
- PAYC N/A
- JAZZ N/A
- Industry
- PAYC Computer Software: Prepackaged Software
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- PAYC Technology
- JAZZ Health Care
- Exchange
- PAYC Nasdaq
- JAZZ Nasdaq
- Market Cap
- PAYC 9.1B
- JAZZ 8.6B
- IPO Year
- PAYC 2014
- JAZZ 2007
- Fundamental
- Price
- PAYC $163.65
- JAZZ $170.80
- Analyst Decision
- PAYC Buy
- JAZZ Strong Buy
- Analyst Count
- PAYC 13
- JAZZ 14
- Target Price
- PAYC $225.42
- JAZZ $181.50
- AVG Volume (30 Days)
- PAYC 792.2K
- JAZZ 1.0M
- Earning Date
- PAYC 11-05-2025
- JAZZ 11-05-2025
- Dividend Yield
- PAYC 0.91%
- JAZZ N/A
- EPS Growth
- PAYC N/A
- JAZZ N/A
- EPS
- PAYC 8.05
- JAZZ N/A
- Revenue
- PAYC $2,001,300,000.00
- JAZZ $4,157,832,999.00
- Revenue This Year
- PAYC $10.98
- JAZZ $5.80
- Revenue Next Year
- PAYC $9.14
- JAZZ $6.06
- P/E Ratio
- PAYC $20.39
- JAZZ N/A
- Revenue Growth
- PAYC 9.72
- JAZZ 4.14
- 52 Week Low
- PAYC $156.50
- JAZZ $95.49
- 52 Week High
- PAYC $267.76
- JAZZ $172.91
- Technical
- Relative Strength Index (RSI)
- PAYC 27.65
- JAZZ 82.88
- Support Level
- PAYC $162.28
- JAZZ $128.80
- Resistance Level
- PAYC $171.35
- JAZZ $144.97
- Average True Range (ATR)
- PAYC 6.21
- JAZZ 5.23
- MACD
- PAYC -1.01
- JAZZ 2.17
- Stochastic Oscillator
- PAYC 18.08
- JAZZ 95.48
About PAYC Paycom Software Inc.
Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.